SWOG clinical trial number
CTSU/A081801
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Open
Phase
Abbreviated Title
Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Status Notes
Effective March 15, 2022, A081801 will be re-activated to accrual.
Activated
06/23/2020
Research committees
Lung Cancer
Treatment
Cisplatin
Carboplatin
Gemcitabine hydrochloride
Radiation Therapy
Pemetrexed
MK-3475
Paclitaxel
Eligibility Criteria Expand/Collapse
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute. Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org) for more information and registration procedures.
Publication Information Expand/Collapse
2021
PMid: PMID33878954 | PMC number: PMC8293026
Other Clinical Trials
SWOG Clinical Trial Number
A082302
EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)
Research Committee(s)
Lung Cancer
Activated
03/02/2027
Open
SWOG Clinical Trial Number
S2409
PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231
A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase